Refine by
Disease Virus Articles & Analysis
39 news found
Due to the large outbreaks of ZIKA virus-associated disease, the World Health Organization declared ZIKA virus a public health emergency of international concern in early 2016, greatly accelerating the pace of global research into ZIKA virus. Several disease models of Zika virus infection have ...
Viral vectors can be used for the treatment of various diseases such as: muscular, metabolic, hematologic, ophthalmologic, and infectious diseases as well as different types of cancer. ...
ByNuvonis
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. These products are only intended for research use, not for diagnostic or clinical purposes. Monkeypox is a rare ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
Indication PreHevbrio is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and older. ...
” PreHevbri was approved by the European Commission (EC) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) in the second quarter of 2022 for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. About Hepatitis B Hepatitis B is one of the world’s most significant infectious ...
About Hepatitis B Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. ...
About Hepatitis B Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. ...
About VBI-1901 and GBM VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. ...
Kanya Rajangam as Chief Medical and Development Officer, to lead Senti Bio's novel off-the-shelf CAR-NK cell oncology programs into and through clinical development Established collaborations with biopharmaceutical companies, Spark Therapeutics and BlueRock Therapeutics, to demonstrate the broad potential of gene circuits, including Smart Sensors to precisely detect distinct cell types or ...
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022. ...
About VBI-1901 and GBM VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. ...
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] for active immunisation against infection caused by all ...
Indication PreHevbrio is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and older. ...
A Phase 2 trial to assess the safety and efficacy of posoleucel for the prevention of infections and disease from the six target viruses is also ongoing. Based on initial data from this Phase 2 multi-virus prevention study, the company plans to initiate a Phase 3 registrational trial for multi-virus prevention in the first half of 2022, following ...
ByKalaris
Angela Huttner, M.D., Infectious Disease Consultant, Geneva University Hospitals, and the lead investigator of the study, said, "We are grateful to our volunteers for their critical role in the development of this vaccine, which we hope will be a key player in future Ebola Virus Disease prevention." ...
The funding will accelerate the launch and broad market availability of the AscencioDx™ molecular diagnostic platform for the detection of RNA indicative of the SARS-CoV-2 / COVID-19 virus. Currently in clinical trials in the U.S., Anavasi expects to file its submission to the U.S. ...
UVD Robots have already been implemented in more than 70 countries worldwide and are currently enabling hospitals to reduce disease transmission by destroying more than 99.99% percent of bacteria and microorganisms within approximately 10-12 minutes in a patient room. ...
UVD Robots have already been implemented in more than 70 countries worldwide and are currently enabling hospitals to reduce disease transmission by destroying more than 99.99% percent of bacteria and microorganisms within approximately 10-12 minutes in a patient room. ...
“Many scientists and public health officials think SARS-CoV-2 is becoming endemic, and we believe Meissa’s intranasal COVID-19 vaccine can contribute to global control of the disease and virus spread,” said Martin Moore, Ph.D., CEO and Cofounder of Meissa Vaccines. ...